TRANSTHYRETIN MEDIATED AMYLOIDOSIS Clinical Trials

12 clinical trials for TRANSTHYRETIN MEDIATED AMYLOIDOSIS across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — RECRUITING
• TRITON-PN: A PHASE 3, GLOBAL, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (HATTR-PN) — RECRUITING · PHASE3
• A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ACORAMIDIS FOR TRANSTHYRETIN AMYLOIDOSIS PREVENTION IN THE YOUNG (ACT-EARLY TRIAL) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID POLYNEUROPATHY — RECRUITING · PHASE3
• PET/CT Imaging in Carriers of TTR Mutations — NOT_YET_RECRUITING
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects — COMPLETED · PHASE1
• A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers — COMPLETED · PHASE1
• A PHASE 3, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACORAMIDIS IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID POLYNEUROPATHY (ATTRIBUTE-PN STUDY) — NOT_YET_RECRUITING · PHASE3
• HELIOS-A: A PHASE 3 GLOBAL, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC02 IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR AMYLOIDOSIS) — COMPLETED · PHASE3
• A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects — COMPLETED · PHASE1
• Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis — COMPLETED · PHASE1

Refine this search